While this is the first jurisdiction to approve the patent, the company has pending applications of the same patent in Europe, the US, India, China and Australia.

The first total artificial heart that mimics the structure and function of the native human heart

Realheart is developing Realheart TAH, the first total artificial heart that mimics the structure and function of the native human heart. The recently approved patent covers a key technology of Realheart TAH, entailing the automated control function of the device. The feature is an important part of the product’s value proposition, designed to provide a meaningful treatment alternative for patients awaiting a heart transplant, while providing benefits that may increase the quality of life. The structural design of Realheart TAH aims to decrease risk factors commonly associated with currently approved artificial heart treatment devices, e.g., stroke, internal bleeding, and anemia.

The patent approval confers market protection for the device in Japan until 2041.